Inside IPEC: Excipient Pedigree as a Supply Chain Tool - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Inside IPEC: Excipient Pedigree as a Supply Chain Tool
It's time to maintain a thorough traceable excipient trail.


Pharmaceutical Technology
Volume 34, Issue 3, pp. 78-79

The data reported on the COA, however, must be based on the manufacturer's analytical testing results and include, as recommended by the IPEC COA guide, the identity and location (including country) of the manufacturer. When a distributor provides its own COA, the manufacturer and the site are identified. If the distributor repackages the excipient or packages from bulk, the distributor must sample, analyze, and include its results in its own COA. A distributor-developed COA should identify the original manufacturer and manufacturing location. Traceability of the exipient manufacturer is required to enable the recall of material.

Furthermore, the position paper suggests that if a distributor receives material into a holding tank, only materials from the same manufacturer's site or terminal conforming to the same specifications should be mixed. Distributors that load or package from bulk excipient should follow the WHO GTDP and IPEC GDP principles regarding definition of batches, analysis of material, and preparation of COAs. The distributor also should have an effective change-management program in place.

The excipient user bears the responsibility for all excipients used and, therefore, must know the origin and complete supply chain (i.e., excipient pedigree) for each batch of each excipient. Apart from performing appropriate testing of each incoming excipient lot, the position paper states that the user should audit both the excipient manufacturer and all distributors in the supply chain, or use the results of an audit. FDA has indicated that it is permissable to use a qualified third-party to conduct these audits and IPEC has published audit guides that can be used for this purpose. It's also important for the user to periodically verify the chain of custody described above to ensure the pedigree's accuracy. All these steps can be completed as part of supplier qualification and supply-chain management.

The final topic addresed in the IPEC excipient pedigree paper is labeling. IPEC recommends excipients never be labeled as compendial material (e.g., USPNF) solely based upon test results. To protect the supply chain, non-GMP material should never be relabeled as compendial grade based solely on conformance to the compendial monograph. The original material must have been manufactured and distributed in conformance with appropriate GMP and GDP requirements, including testing, storage, repackaging, and relabeling.

Verifying the pedigree of an excipient with a paper trail (or electronic paper trail) only works with the cooperation of everyone involved in the supply chain. If a single party fails to adopt these preventive measures voluntarily, verification may eventually be mandated by more burdensome and costly regulations.

Arthur J. Falk, PhD, is president and CEO of International Pharmaceutical Excipient Auditing (IPEA), tel. 908.735.812,
. The IPEC documents mentioned in this article can be downloaded for free at http://www.ipecamericas.org/.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
24%
Attracting a skilled workforce
30%
Obtaining/maintaining adequate financing
15%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here